REPLIGEN CORP
Repligen (RGEN) shares rose 27.7% since its last earnings report, beating Q2 estimates with $0.54 EPS and $204.1M revenue. The company raised 2026 guidance, expecting $813M-$835M revenue and $2.03-$2.09 EPS. Analysts have upwardly revised estimates, giving RGEN a Zacks Rank #1 (Strong Buy).
MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.
Repligen (RGEN) CEO Olivier Loeillot exercised 5,426 stock options at $141.79 per share and sold the shares at $180 each under a 10b5-1 plan, according to a Form 4 filing. The transaction occurred on August 20, 2026, and 10,852 options remain outstanding. Additional shares will vest in 2026 and 2027.
Over the past 7 days, alphai's AI scored 3 news stories mentioning RGEN (REPLIGEN CORP). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent RGEN coverage spans earnings, mergers & acquisitions and technology.
In the last 30 days, RGEN insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($977K). The most active reporter was Loeillot Olivier, Chief Executive Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Earnings beat and upgraded guidance suggest stronger near‑term earnings momentum.
Bioprocessing demand could rise with successful cell‑therapy commercialization.
CEO sold shares for $977K, indicating potential confidence level and short-term supply pressure.
Insider sale may signal slight negative sentiment but size is modest relative to float.
Guidance lift and acquisition signal stronger growth, likely supporting further price upside.
alphai scores every news story that mentions RGEN with an AI model for sentiment and relevance, and aggregates insider trades from REPLIGEN CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Repligen (RGEN) shares rose 27.7% since its last earnings report, beating Q2 estimates with $0.54 EPS and $204.1M revenue. The company raised 2026 guidance, expecting $813M-$835M revenue and $2.03-$2.09 EPS. Analysts have upwardly revised estimates, giving RGEN a Zacks Rank #1 (Strong Buy).
2 min readMRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.
3 min readRepligen (RGEN) CEO Olivier Loeillot exercised 5,426 stock options at $141.79 per share and sold the shares at $180 each under a 10b5-1 plan, according to a Form 4 filing. The transaction occurred on August 20, 2026, and 10,852 options remain outstanding. Additional shares will vest in 2026 and 2027.
1 min readLoeillot Olivier (Chief Executive Officer) sold 5,426 shares of REPLIGEN CORP (RGEN) at $180.00 ($0.98M total) on 2026-08-20 under a Rule 10b5-1 trading plan.
1 min readRepligen (RGEN) shares rose 3.5% following strong Q2 2026 results, raised 2026 guidance, and the planned BioLife Solutions acquisition. Revenue was $204M with double-digit YoY growth. Full-year 2026 organic revenue growth guidance increased to 10.5%-13.5%, and adjusted EPS outlook raised to $2.03-$2.09. The BioLife deal, valued at $1.5B, is expected to expand Repligen's cell therapy tools.
2 min readShares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.
2 min readThe article reviews Q2 results for drug development inputs and services stocks, noting the group’s revenues beat analysts’ consensus by 4.1% and next-quarter guidance was 0.8% above. Repligen (RGEN) reported $204.1M revenue, up 11.9% YoY, beating expectations by 1.1%. It also cites Azenta (AZTA), IQVIA (IQV), Charles River (CRL), and West (WST) with their Q2 revenue figures and stock moves.
6 min readBioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.
2 min readSimply Wall St reports Repligen (RGEN) rose 6.9% after Q2 2026 results. Revenue increased to $204.13M from $182.37M, but net income fell to $5.01M from $14.87M and diluted EPS declined to $0.09 from $0.26. Analysts reportedly raised earnings estimates despite margin pressure and noted Russell index removals.
4 min readMorgan Stanley research cited by the article says the median S&P 500 EPS surprise was 6% in Q1 2026, above the long-run ~5.5% average. FactSet research cited says firms with positive EPS surprises tend to keep outperforming after results. The article lists 28 companies that beat Wall Street EPS expectations, including Ford (EPS $0.66 vs $0.31), Bloom Energy (EPS $0.78 vs $0.37; revenue >$1B, +164% YoY), and Incyte (EPS $3.09 vs $0.94).
7 min read
